Lipocine Inc
For the period ended Dec 31, 2023. Filed Mar 7, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 7, 2024
LPCN$1.59-7.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
| Years Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Revenues: | ||
| License revenue | $109,987 | $500,000 |
| Minimum guaranteed royalties revenue (reversal of variable consideration) | (2,960,805) | - |
| Total revenues (reversal of variable consideration), net | (2,850,818) | 500,000 |
| Operating expenses: | ||
| Research and development | 10,175,251 | 8,556,888 |
| General and administrative | 4,904,888 | 4,062,487 |
| Total operating expenses | 15,080,139 | 12,619,375 |
| Operating loss | (17,930,957) | (12,119,375) |
| Other income (expense): | ||
| Interest and investment income | 1,366,940 | 572,578 |
| Interest expense | - | (27,098) |
| Unrealized gain on warrant liability | 212,690 | 565,940 |
| Gain on litigation settlement liability | - | 250,000 |
| Total other income, net | 1,579,630 | 1,361,420 |
| Loss before income tax expense | (16,351,327) | (10,757,955) |
| Income tax expense | (755) | (681) |
| Net loss | (16,352,082) | (10,758,636) |
| Issuance of Series B preferred stock dividend | (89) | - |
| Net loss attributable to common shareholders Net loss attributable to common shareholders | $(16,352,171) | $(10,758,636) |
| Basic loss per share attributable to common stock | $(3.10) | $(2.06) |
| Weighted average common shares outstanding, basic | 5,269,671 | 5,231,681 |
| Diluted loss per share attributable to common stock | $(3.14) | $(2.15) |
| Weighted average common shares outstanding, diluted | 5,269,671 | 5,256,169 |
| Comprehensive loss: | ||
| Net loss | $(16,352,082) | $(10,758,636) |
| Net unrealized gain (loss) on available-for-sale securities | 27,580 | (2,305) |
| Comprehensive loss | $(16,324,502) | $(10,760,941) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.